Welcome to our dedicated page for Oncocyte Corporation SEC filings (Ticker: OCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Oncocyte Corp. (Nasdaq: OCX), identified in recent reports as Insight Molecular Diagnostics Inc., provides access to the company’s official regulatory disclosures. These documents include current reports on Form 8-K, periodic reports, proxy materials, and other filings that describe financial performance, shareholder votes, capital raising transactions, and key corporate developments. For example, a Form 8-K dated August 11, 2025 reports on financial results for the six months ended June 30, 2025, while a Form 8-K dated July 2, 2025 details the outcomes of the company’s 2025 annual meeting of shareholders.
Through these filings, investors can review information about director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and amendments to equity incentive plans. The filings also reference the company’s corporate name as Insight Molecular Diagnostics Inc., its jurisdiction of incorporation in California, and its Commission file number, providing context on its legal and reporting status.
Oncocyte’s SEC filings complement its public news releases about its diagnostics programs in transplant rejection testing and oncology. While press releases describe scientific, clinical, and commercial progress for products such as GraftAssureCore, GraftAssureIQ, GraftAssureDx, DetermaIO, and DetermaCNI, the SEC reports supply audited financial data, management’s discussion of results, and formal records of shareholder actions. Together, these materials help investors understand how the company is funding and governing its efforts to develop and commercialize dd-cfDNA-based transplant assays and oncology diagnostics.
On Stock Titan, users can access Oncocyte’s SEC filings as they are made available through EDGAR and use AI-powered tools to read summaries and identify key points in lengthy documents. This can help clarify topics such as results of operations, financial condition, shareholder voting outcomes, and the structure of equity incentive plans, all within the context of Oncocyte’s broader diagnostics technology strategy.
Insight Molecular Diagnostics Inc. (f/k/a Oncocyte) reported a noticeable uptick in commercial activity with net revenue of $518,000 for the quarter ended June 30, 2025 versus $104,000 a year earlier, and $2.656 million for the six months versus $280,000. Revenue growth was driven primarily by laboratory services and initial sales of the GraftAssureIQ kitted product.
Results show widening losses: a net loss of $9.742 million in the quarter (six-month loss of $16.413 million), as operating expenses rose to $10.192 million for the quarter, including a $2.804 million charge for the change in fair value of contingent consideration. Liquidity improved materially following a February 2025 registered offering that raised gross proceeds of approximately $29.1 million (net proceeds ~$28.7 million), leaving cash and cash equivalents of $24.3 million and combined cash plus restricted cash of $26.0 million at period end.
Operational and strategic developments include a corporate name and ticker change to IMDX and headquarters relocation to Nashville, an ongoing strategic partnership and investment with Bio-Rad, and a boosted Medicare reimbursement rate of $2,753 per result for GraftAssureCore. Significant noncurrent contingent consideration of $40.933 million and an accumulated deficit of $366.95 million remain on the balance sheet. Management concluded there is no substantial doubt about going concern for at least the next twelve months.
Insight Molecular Diagnostics Inc. filed a current report to state that it released a press release with its financial results for the six months ended June 30, 2025. The company explains that the press release, dated August 11, 2025 and attached as Exhibit 99.1, contains details on its results of operations and financial condition for that period. The information in this section is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings unless specifically referenced.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
